|
Best brain response
|
CR
|
PR
|
Any Response
|
SD ≥ 6mo
|
SD < 6mo
|
PD
|
Total
|
Log-rank test for treatment,P-value
|
|---|
|
Treatment before entering the study
|
No.
|
Median brain PFS, wk (95 % CI)
|
No.
|
Median brain PFS, wk (95 % CI)
|
No.
|
Median brain PFS, wk (95 % CI)
|
No.
|
Median brain PFS, wk (95 % CI)
|
No.
|
Median brain PFS, wk (95 % CI)
|
No.
|
Median brain PFS, wk (95 % CI)
|
No.
|
Median brain PFS, wk (95 % CI)
| |
|---|
|
No
|
0
|
NE
|
2
|
59.3 (NE)
|
0
|
NE
|
1
|
30.4 (NE)
|
1
|
12.6 (NE)
|
2
|
9.2 (6.4-12.0)
|
6
|
21.5 (12.0-59.3)
|
0.6281
|
|
Excision/GKS/ SRS/FSRT
|
4
|
32.4 (21.6-34.7)
|
0
|
NE
|
6
|
27.5 (20.0-53.7)
|
2
|
36.4 (28.1-44.7)
|
0
|
NE
|
0
|
NE
|
12
|
31.4 (22.1-34.7)
| |
|
WBRT
|
2
|
84.3 (NE)
|
4
|
21.1 (15.9-NE)
|
13
|
40.9 (25.0-59.0)
|
5
|
35.0 (26.1-NE)
|
3
|
17.9 (12.6-24.0)
|
5
|
10.7 (4.0-32.6)
|
32
|
31.1 (23.7-41.0)
| |
|
Subtotal
|
6
|
33.6 (30.4-84.3)
|
6
|
42.4 (16.6-NE)
|
19
|
32.9 (23.7-54.1)
|
8
|
33.2 (28.1-48.6)
|
4
|
15.2 (12.6-24.0)
|
7
|
10.7 (6.4-12.1)
|
50
|
30.6 (24.0-34.7)
| |
|
IT MTX
| | | | |
1
|
17.0 (NE)
| | | | | | |
1
|
17.0 (NE)
| |
|
Total
|
6
|
33.6 (30.4-84.3)
|
6
|
42.4 (16.6-NE)
|
20
|
32.8 (22.1-54.1)
|
8
|
33.2 (28.1-48.6)
|
4
|
15.2 (12.6-24.0)
|
7
|
10.7 (6.4-12.1)
|
51
|
30.4 (23.7-34.7)
| |
- CR, complete response; FSRT, fractionated stereotactic radiotherapy; GKS, gamma knife surgery; IT MTX, intrathecal methotrexate; PR, partial response; PD, progressive disease; SD, stable disease; SRS, stereotactic radio-surgery; WBRT, whole-brain radiotherapy; NE, not estimable.
